BACKGROUND: Hepatitis C infection is a major health problem worldwide, especially in Egypt. The high prevalence of mixed cryoglobulinemia (MC) in hepatitis C patients leads to the assumption that there is a direct link between hepatitis C virus (HCV) and cryoglobulinemia. Host genetic factors could be a contributing factor. B cell-activating factor (BAFF) is a tumor necrosis factor (TNF) family member, which has an essential role in B lymphocyte development and survival. The aim of the present work was to study the possible association between the BAFF -871C/T promoter polymorphism and HCV-related MC in a cohort of Egyptian patients. METHODS: The study was conducted in 120 HCV patients classified into two groups: group I (60 HCV patients with MC) and group II (60 HCV patients without MC), with 60 age- and sex-matched healthy control subjects. BAFF -871C/T genotyping was performed in all subjects by polymerase chain reaction (PCR) with restriction fragment length polymorphism analysis. RESULTS: The prevalence of the BAFF -871TT genotype was significantly increased in HCV patients compared with the control group (P=0.036). The BAFF TT genotype was also significantly more prevalent in group I (HCV-MC patients) than in group II (HCV patients without MC) [P<0.001]. CONCLUSION: A significant association was found between the BAFF -871C/T promoter polymorphism and MC, which may indicate that BAFF could be a potential therapeutic target in HCV-MC.
BACKGROUND:Hepatitis C infection is a major health problem worldwide, especially in Egypt. The high prevalence of mixed cryoglobulinemia (MC) in hepatitis C patients leads to the assumption that there is a direct link between hepatitis C virus (HCV) and cryoglobulinemia. Host genetic factors could be a contributing factor. B cell-activating factor (BAFF) is a tumor necrosis factor (TNF) family member, which has an essential role in B lymphocyte development and survival. The aim of the present work was to study the possible association between the BAFF-871C/T promoter polymorphism and HCV-related MC in a cohort of Egyptian patients. METHODS: The study was conducted in 120 HCVpatients classified into two groups: group I (60 HCVpatients with MC) and group II (60 HCVpatients without MC), with 60 age- and sex-matched healthy control subjects. BAFF-871C/T genotyping was performed in all subjects by polymerase chain reaction (PCR) with restriction fragment length polymorphism analysis. RESULTS: The prevalence of the BAFF -871TT genotype was significantly increased in HCVpatients compared with the control group (P=0.036). The BAFF TT genotype was also significantly more prevalent in group I (HCV-MC patients) than in group II (HCVpatients without MC) [P<0.001]. CONCLUSION: A significant association was found between the BAFF-871C/T promoter polymorphism and MC, which may indicate that BAFF could be a potential therapeutic target in HCV-MC.
Authors: M Fabris; L Quartuccio; S Sacco; G De Marchi; G Pozzato; C Mazzaro; G Ferraccioli; T S Migone; S De Vita Journal: Rheumatology (Oxford) Date: 2006-05-30 Impact factor: 7.580
Authors: Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: M Marín-Rosales; A Cruz; D C Salazar-Camarena; E Santillán-López; N Espinoza-García; J F Muñoz-Valle; M G Ramírez-Dueñas; E Oregón-Romero; G Orozco-Barocio; C A Palafox-Sánchez Journal: Clin Exp Med Date: 2019-02-11 Impact factor: 5.057